AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
1. AbbVie reported Q3 2025 sales of $15.78 billion, surpassing expectations. 2. Quarterly dividend increased to $1.73 due to strong business performance. 3. Immunology sales grew 11.9%, driven by Skyrizi and Rinvoq. 4. Analysts see potential growth from Parkinson's disease treatments and ADCs. 5. ABBV shares fell 3.70% to $219.76 despite positive earnings news.